English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

In an elegantly written paper, Haahr and colleagues from Odense, Denmark, document the first phase 1 trial using autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy. These results have long been awaited. In 2010, Tom Lue's group at UCSF published the first preclinical data on adipose tissue derived stem cell treatment in a rat model of cavernous nerve neuropraxia (a model that accurately and efficiently represents the pathophysiology of erectile dysfunction following nerve-sparing radical prostatectomy) (Albersen et al., 2010). Now six years later, the first clinical trial studying injection of regenerative cells derived from adipose tissue is published in EBioMedicine (Haahr et al., 2016). The advent of the first clinical data forces us as a scientific community to contemplate on whether or not we are ready for clinical translation of stem cell therapy for a non-lethal disease.

Regenerative Medicine for Erectile Dysfunction Following Radical Prostatectomy: Are we Ready?